Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TPA DRUG COSTS, PERSONNEL INTENSITY PER CASE TO BE STUDIED BY MTPPI

Executive Summary

TPA DRUG COSTS, PERSONNEL INTENSITY PER CASE TO BE STUDIED BY MTPPI, with Genentech funding. Hospital costs for tissue plasminogen activator, including associated personnel expenses, will be surveyed by the Medical Technology and Practice Patterns Institute, with funding from Genentech, maker of Activase. The study, still in the design stages, will span three to four years. Initial results may be available in mid-1989, MTPPI staff said. The institute is a Washington, D.C. research and consulting firm, which focuses primarily on technology utilization and Medicare reimbursement. Genentech is providing about $18,000 in first-year funding for the project. In addition, hospitals that participate in the study will each contribute about $4,000. Hospitals that participate in an MTPPI survey receive data comparing their use profiles for a technology with industry-wide averages. The institute hopes to have a 10% representative sample of hospitals using TPA. For the study, the institute will assess pharmacy costs for the clot-dissolving drug, including expenses for ordering and stocking. It also will gauge the costs for hospital workers to administer the drug and monitor patients. In addition, the study will analyze: - - the Medicare diagnosis-related groups used for patients receiving TPA; - - patient complications and comorbidities; - - other procedures that TPA patients undergo; - - treatment costs versus DRG reimbursement rates; and, - - utilization and cost differences for patients under and over age 70. The study will not look at alternative heart attack therapies, such as streptokinase.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS014708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel